drugset / Trial / NCT07302347

A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21/KEYNOTE-G21)

NCT07302347

Phase 1/2 Recruiting 20 enrolled Merck Sharp & Dohme LLC
Non-randomizedParallel-groupSingle-blindTreatment

Summary

Researchers are looking for new ways to treat people with solid tumors, lymphomas (blood cancers), and a certain type of skin cancer. The goals of this study are to learn: * About the safety of pembrolizumab (the study medicine) and if people tolerate it * What happens to different doses of pembrolizumab in a person's body over time * How the cancer responds (gets smaller or goes away) to treatment

Timeline

Start
2026-06-23
Primary completion
2029-03-30
Completion
2029-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Pembrolizumab Monoclonal antibody 2 mg/kg Intravenous
Subject Pembrolizumab Monoclonal antibody 400 mg Intravenous